Aligos Therapeutics (ALGS) announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer. Hassard will lead and build the Company’s global commercial capabilities and serve as a member of Aligos’ Senior Leadership Team. Prior to joining Aligos, Jim was CCO at Crinetics Pharmaceuticals and Arrowhead Pharmaceuticals.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics initiated with a Buy at UBS
- Aligos Therapeutics announces inducement grants under Nasdaq listing rule
- Aligos Therapeutics: Promising Developments in Liver Disease Programs and Strategic Pipeline Drive Buy Rating
- Aligos Therapeutics presents pevifoscorvir, ALG-055009 data at HEP-DART
- Aligos Therapeutics: Strong Buy Rating Backed by Promising Liver Disease Treatments and Strategic Positioning